SUBSCRIBE
SUBSCRIBE
News   Policy

Orexigen Therapeutics, Inc. Revises Obesity Drug, Contrave Data

April 14, 2010 | 
1 min read

Reuters -- Orexigen Therapeutics Inc said on Tuesday that fewer patients achieved key weight loss goals when taking its experimental obesity drug than originally reported, sending the company’s stock down 11 percent.

Regulatory
MORE ON THIS TOPIC
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac